• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead

    8/21/23 10:27:38 PM ET
    $ADPT
    $CDXS
    $CELL
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials
    Get the next $ADPT alert in real time by email

    On Monday, August 21, 2023, Cathie Wood-led Ark Invest made significant moves in the market, with a notable decision to sell $9.2 million worth of shares of Shopify Inc (NYSE:SHOP). This comes in the wake of Shopify's recent volatility following its Q2 results.

    The Shopify Trade: Ark sold 170335 shares of Shopify through ARK Next Generation Internet ETF (NYSE:ARKW) and Ark Fintech Innovation ETF (NYSE:ARKF). The transaction was valued at $9.2 million, based on Shopify stock’s closing price of $53.93 on Monday.

    Ark Invest’s decision to sell Shopify shares across various ETFs is a continuation of its recent trading behavior.

    Earlier this week, Ark Invest also made a notable decision to sell Shopify shares. All in all, Ark sold $8.9 million of Shopify shares.

    See Also: Is Nvidia Overpriced? Cathie Wood’s Ark Invest Points To 3 Other Stocks

    Other Key Trades:

    • Ark Invest bought 2889 shares of ADYEN NV (OTC:ADYEY) through ARKF and 733,462 shares through ARKW.
    • Ark Invest bought 7017 shares of CRISPR THERAPEUTICS AG (NASDAQ:CRSP) through ARK Genomic Revolution ETF (BATS:ARKG).
    • Ark Invest bought 32165 shares of ADAPTIVE BIOTECHNOLOGIES (NASDAQ:ADPT) through ARKG.
    • Ark Invest bought 37638 shares of RECURSION PHARMACEUTICALS (NASDAQ:RXRX) through ARKG.
    • Ark Invest sold 249538 shares of CODEXIS INC (NASDAQ:CDXS) through ARKG.
    • Ark Invest sold 249507 shares of PHENOMEX INC (NASDAQ:CELL) through ARKG.

    Read Next: Palantir Post-Q2 Earnings: Share Price Dip Doesn’t Deter Cathie Wood; Ark Invest Buys $14M Worth Of Shares


    Engineered by Benzinga Neuro, Edited by Shivdeep Dhaliwal


    The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT
    $CDXS
    $CELL
    $CRSP

    CompanyDatePrice TargetRatingAnalyst
    Shopify Inc.
    $SHOP
    3/12/2026$165.00Overweight
    Piper Sandler
    Shopify Inc.
    $SHOP
    2/17/2026$150.00Hold → Buy
    Truist
    Shopify Inc.
    $SHOP
    2/12/2026$150.00Neutral → Outperform
    Mizuho
    Shopify Inc.
    $SHOP
    2/12/2026$159.00Hold → Buy
    TD Cowen
    Shopify Inc.
    $SHOP
    2/10/2026$150.00Neutral → Buy
    MoffettNathanson
    Shopify Inc.
    $SHOP
    2/2/2026Neutral → Buy
    Arete
    Shopify Inc.
    $SHOP
    1/8/2026Sector Perform → Sector Outperform
    Scotiabank
    Shopify Inc.
    $SHOP
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ADPT
    $CDXS
    $CELL
    $CRSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $CDXS
    $CELL
    $CRSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Patel Naimish bought $49,704 worth of shares (1,508 units at $32.96) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    1/27/26 5:35:15 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Treco Douglas A bought $1,140,600 worth of shares (20,000 units at $57.03), increasing direct ownership by 1,000% to 22,000 units (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    8/8/25 4:06:28 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Opaleye Management Inc. bought $227,921 worth of shares (85,000 units at $2.68) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    8/4/25 4:38:06 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $ADPT
    $CDXS
    $CELL
    $CRSP
    SEC Filings

    View All

    SEC Form 144 filed by Shopify Inc.

    144 - SHOPIFY INC. (0001594805) (Subject)

    4/6/26 4:25:15 PM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    SEC Form PRE 14A filed by CRISPR Therapeutics AG

    PRE 14A - CRISPR Therapeutics AG (0001674416) (Filer)

    4/2/26 4:23:21 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Recursion Pharmaceuticals Inc.

    SCHEDULE 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    3/27/26 11:36:08 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $CDXS
    $CELL
    $CRSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Recursion to Participate in Upcoming Investor Conferences

    Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: 25th Annual Needham Virtual Healthcare Conference - Monday, April 13, 2026 Bank of America Health Care Conference 2026 - Tuesday, May 12, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational med

    4/7/26 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

    ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, Apr 13 at 2:15 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR TherapeuticsFounded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative

    4/7/26 8:00:00 AM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

    NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a leading tech-bio company decoding biology through advanced data science and automation. Recursion's end-to-end platform is designed to connect discovery through development by integrating proprietary multimodal datasets, purpose-built AI models, and experimental biology. The addition of Citeline's real-world data and evidence capabilities strengthens this foundation, enabling more precise trial design, improved site selection, and faster, more informed development decisions

    3/31/26 9:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $CDXS
    $CELL
    $CRSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Shopify with a new price target

    Piper Sandler resumed coverage of Shopify with a rating of Overweight and set a new price target of $165.00

    3/12/26 8:55:08 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Shopify upgraded by Truist with a new price target

    Truist upgraded Shopify from Hold to Buy and set a new price target of $150.00

    2/17/26 8:04:32 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Shopify upgraded by Mizuho with a new price target

    Mizuho upgraded Shopify from Neutral to Outperform and set a new price target of $150.00

    2/12/26 7:19:59 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    $ADPT
    $CDXS
    $CELL
    $CRSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Taylor Ben R

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/8/26 4:58:31 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Gibson Christopher

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/8/26 4:58:25 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Borgeson Blake

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/8/26 4:58:18 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $CDXS
    $CELL
    $CRSP
    Leadership Updates

    Live Leadership Updates

    View All

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

    Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and a Board Member, will succeed Co-Founder and CEO Chris Gibson, Ph.D., as Chief Executive Officer and President. Najat will also continue in her role as a member of the Board of Directors.  Chris Gibson, Ph. D., current Co-Founder and CEO, will transition to Chairman of the Board of Directors and an interim Executive Adv

    11/5/25 6:28:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $CDXS
    $CELL
    $CRSP
    Financials

    Live finance-specific insights

    View All

    Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

         Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis

    3/11/26 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domest

    2/25/26 9:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $CDXS
    $CELL
    $CRSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

    SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/13/24 4:30:24 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

    SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/13/24 9:00:21 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care